Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Merz Therapeutics
Deal Size : $185.0 million
Deal Type : Acquisition
Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics
Details : Merz purchases substantially all of the assets of Acorda, including the rights to Inbrija (levodopa inhalation powder), which is used when needed for OFF episodes in adults with Parkinson's disease.
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Merz Therapeutics
Deal Size : $185.0 million
Deal Type : Acquisition
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Merz Pharma
Deal Size : $185.0 million
Deal Type : Acquisition
Merz Enters Asset Purchase Agreement With a US-based Biotech Company
Details : Merz Therapeutics will acquire Acorda's assets, including Inbrija (levodopa inhalation) for OFF episodes in Parkinson’s and Ampyra (dalfampridine).
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 02, 2024
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Merz Pharma
Deal Size : $185.0 million
Deal Type : Acquisition
Lead Product(s) : Fampridine
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Biogen
Deal Size : $510.0 million
Deal Type : Termination
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
Details : Following termination, Acorda regains global commercialization rights to Fampyra, a prolonged-release formulation of fampridine (4-aminopyridine) for adults with multiple sclerosis.
Brand Name : Fampyra
Molecule Type : Small molecule
Upfront Cash : $110.0 million
January 11, 2024
Lead Product(s) : Fampridine
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Biogen
Deal Size : $510.0 million
Deal Type : Termination
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inha...
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 06, 2023
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Chance Pharmaceuticals
Deal Size : $144.0 million
Deal Type : Agreement
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
Details : The collaboration aims to provide INBRIJA® in China. Inbrija (levodopa) is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase...
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : $2.5 million
May 08, 2023
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Chance Pharmaceuticals
Deal Size : $144.0 million
Deal Type : Agreement
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Esteve Quimica
Deal Size : Not Applicable
Deal Type : Not Applicable
ESTEVE Launches INBRIJA® in Spain
Details : Inbrija (levodopa) is levodopa/dopa-decarboxylase inhibitor, it is converted to dopamine replacement agent for the intermittent treatment of episodic motor fluctuations of Parkinson disease.
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 07, 2023
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Esteve Quimica
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Recipient : Catalent Pharma Solutions
Deal Size : $10.0 million
Deal Type : Agreement
Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®
Details : INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inha...
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 05, 2023
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Recipient : Catalent Pharma Solutions
Deal Size : $10.0 million
Deal Type : Agreement
Lead Product(s) : Nepicastat
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Asieris Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Acorda Therapeutics Enters into License Agreement with Asieris Pharmaceuticals
Details : SYN117 (nepicastat), is a small molecule drug and the license agreement provides for its development for all non-psychiatric indications and therapeutic uses. The asset has been held by Acorda’s U.S. subsidiary, Biotie Therapies, Inc.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : $0.5 million
August 29, 2022
Lead Product(s) : Nepicastat
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Asieris Pharmaceuticals
Deal Size : $7.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Esteve Huayi Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Esteve Launches INBRIJA® in Germany
Details : INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) is indicated in the EU for the intermittent treatment of episodic motor uctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibito...
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 16, 2022
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Esteve Huayi Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Biopas Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreements, Acorda will receive a significant percentage of the selling price of INBRIJA in Latin America in exchange for supply of the product. Biopas plans on seeking marketing authorization in all countries to make Inbrija avail...
Brand Name : Inbrija
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 11, 2022
Lead Product(s) : Etilevodopa
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Biopas Laboratories
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?